23. Macklon N.S., Fauser B.C. Impact of ovarian hyperstimulation on the luteal phase. J. Reprod. Fertil. Suppl. 2000; 55: 101–108.
24. IVF Worldwide. An updated survey: the use of progesterone for luteal phase support. Доступно по ссылке http://www.ivf-worldwide.com/survey/an-updated-survey-on-the-use-of-progesterone-for-luteal-phase-support-in-stimulated-ivf-cycles/results-an-updated-survey-on-the-use-of-progesterone-for-luteal-phase-support-in-stimulated-ivf-cycles.html.
25. ESHRE Early Pregnancy Guideline Development Group. Recurrent pregnancy loss: guideline of the European Society of Human Reproduction and Embryology. 2017.
26. Abbott Laboratories. Company Core Data Sheet. Dydrogesterone. 5 июля 2017 г.
27. Besins Healthcare (UK) Ltd. Utrogestan 100 mg oral capsules. Summary of Product Characteristics UK. 14 июля 2017 г.
28. Besins Healthcare (UK Ltd. Utrogestan vaginal 200 mg capsules. Summary of Product Characteristics UK. 29 June 2017.
29. Linden M., Buckingham K., Farquhar C. et al. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev 2015: CD009154.
30. Czajkowski K., Sienko J., Mogilinski M., Bros M., Szczecina R., Czajkowska A. Uteroplacental circulation in early pregnancy complicated by threatened abortion supplemented with vaginal micronized progesterone or oral dydrogesterone. Fertil. Steril. 2007; 87: 613–618. doi: 10.1016/j.fertnstert.2006.07.1506.
31. Guerra J.A., López-Muñoz F., Álamo C. Progestins in combined contraceptives. J Exp. Clin. Med. 2013; 5: 51–55. doi: 10.1016/j. jecm.2013.02.007.
32. Davar R., Farid Mojtahedi M., Miraj S. Effects of single dose GnRH agonist as luteal support on pregnancy outcome in frozen-thawed embryo transfer cycles: an RCT. Iran J Reprod Med. 2015; 13(8): 483: 488–710.
33. Yanushpolsky E.H. Luteal phase support in in vitro fertilization. Semin Reprod Med. 2015; 33(2): 118–127.
34. Tournaye H., Sukhikh G.T., Kahler E., Griesinger G. A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization. Hum Reprod. 2017; 32(5): 1019–1027.
35. Vaisbuch E., Leong M., Shoham Z. Progesterone support in IVF: is evidence-based medicine translated to clinical practice? A worldwide web-based survey. Reprod Biomed Online. 2012; 25(2): 139–145.
36. Makhmudova G.M., Nazhmutdinova D.K., Gafarova D.K., Lukmanova Y.D. Efficacy of duphaston treatment in women with endometriosis after reconstructive surgery. Akush. Ginekol. (Sofiia). 2003; 42: 42–46.
37. Mirza F.G., Patki A., Pexman-Fieth C. Dydrogesterone use in early pregnancy. Gynecol. Endocrinol. 2016; 32: 97–106. doi: 10.3109/09513590.2015.1121982. Moszkowski E., Woodruff J.D., Jones G.E. The inadequate luteal phase. Am. J. Obstet. Gynecol. 1962; 83: 363–372.
38. Rižner T.L., Brožič P., Doucette C. et al. Selectivity and potency of the retroprogesterone dydrogesterone in vitro. Steroids. 2011; 76(6): 607–615.
39. Schindler A.E., Campagnoli C., Druckmann R. et al. Classification and pharmacology of progestins. Maturitas. 2008; 61(1–2): 171–180.
40. Stanczyk F.Z., Hapgood J.P., Winer S. et al. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev. 2013; 34(2): 171–208; doi: 10.1210/er.2012-1008.
41. Abbott B.V. 8 June 2017. Duphaston 10, film-coated tablets 10 mg Summary of Product Characteristics.
42. Arvidsson C., Hellborg M., Gemzell-Danielsson K. Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone. Eur. J. Obstet. Gynecol. Reprod. Biol. 2005; 123: 87–91. doi: 10.1016/j.ejogrb.2005.02.019.
43. Bingham J.S. Single blind comparison of ketoconazole 200 mg oral tablets and clotrimazole 100 mg vaginal tablets and 1% cream in treating acute vaginal candidosis. Br. J. Vener. Dis. 1984; 60: 175–177.
44. Chakravarty B.N., Shirazee H.H., Dam P., Goswami S.K., Chatterjee R., Ghosh S. Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. J. Steroid Biochem. Mol. Biol. 2005; 97: 416–420. doi: 10.1016/j.jsbmb.2005.08.012.
45. Patki A., Pawar V.C. Modulating fertility outcome in assisted reproductive technologies by the use of dydrogesterone. Gynecol Endocrinol. 2007; 23(Suppl 1): 68–72.
46. Paulson R.J., Collins M.G., Yankov V.I. Progesterone Pharmacokinetics and Pharmacodynamics With 3 Dosages and 2 Regimens of an Effervescent Micronized Progesterone Vaginal Insert. J Clin Endocrinol Metab. 2014; 99(11): 4241–4249.
47. Tavaniotou A., Smitz J., Bourgain C., Devroey P. Comparison between different routes of progesterone administration as luteal phase support in infertility treatments. Hum Reprod Update. 2000; 6(2): 139–148.
48. Reerink E.H., Scholer H.F., Westerhof P., Querido A., Kassenaar A.A., Diczfalusy E., Tillinger K.C. A new class of hormonally active steroids. Nature. 1960; 186: 168–169.
49. Zafardoust S., Jeddi-Tehrani M., Mehdi Akhondi M. et al. Effect of Administration of Single Dose GnRH Agonist in Luteal Phase on Outcome of ICSI-ET Cycles in Women with Previous History of IVF/ICSI Failure: A Randomized Controlled Trial. J Reprod Infertil. 2015; 16(2): 96–101.